Antibiotic resistance is a major health threat worldwide. An existing problem only set to worsen, addressing this crisis of modern medicine is a now a global imperative.
Nylexa™ is one potential solution to the worsening antibiotic resistance crisis and a strategy that could be introduced into clinical practice within a much shorter timescale than any new antibiotic(s) developed from first principle.
Derived from the same aminothiol platform as Lynovex®, Nylexa™ is an antibiotic potentiator/resistance breaking agent being developed as a parenterally administered adjunct to a number of antibiotic classes; extending their utility and scope against drug resistant, even MDR and XDR bacterial infections. Put simply, when used alongside certain existing antibiotics against drug resistant bacterial pathogens, Nylexa™ allows that antibiotic to work again or work better than it did before, both in terms of potency (dose required) and spectrum of activity. Nylexa™ is antibiotic in its own right but is intended primarily as an adjunct agent.
Importantly, resistance breakers such as Nylexa™ have a faster route to clinic than antibiotic NCEs and as a repurposed aminothiol, Nylexa's development could be further expedited on the basis of existing clinical data in other indications. In vitro and in vivo data generated thus far have demonstrated Nylexa’s efficacy in a number of infection models, supported by Lynovex® clinical data.
“We must increase the supply of new antimicrobials effective against drug-resistant drugs”
AB21 9TR, UK
Tel: +44 (0)1224 711377
9121 Anson Way,
North Carolina 27615, US